Noxopharm Ltd Requests FDA Pre IND Meeting for Autoimmune Skin Drug
Noxopharm requests pre-IND meeting with US FDA to advance SOF-SKN
Clinical-stage biotech company Noxopharm Limited (ASX:NOX) has formally requested a pre-Investigational New Drug (IND) meeting with the US Food & Drug Administration (FDA) to advance its autoimmune disease drug candidate, SOF-SKN.
The company expects the meeting to occur in around two months’ time. The step is intended to help de-risk SOF-SKN’s development and prepare for a future IND submission, while enhancing the drug candidate’s appeal to potential industry partners.
When big ASX news breaks, our subscribers know first
What the FDA milestone means for SOF-SKN
Pre-IND meetings represent an important step in the drug development process. According to the company, the meeting will cover the planned clinical development pathway alongside product manufacturing, quality controls, and other requirements needed to support a comprehensive IND application.
Key highlights from the announcement include:
-
An important regulatory milestone in SOF-SKN’s development
-
A meeting expected in around two months’ time
-
Support for the SOF-SKN clinical pathway
In parallel with the US regulatory track, Noxopharm noted it continues to actively investigate prospects for a near-term pilot study in a local Australian patient population.
For investors, a successful application stands to increase SOF-SKN’s commercial potential and make the drug more attractive to potential industry partners in both the US and elsewhere.
Dr Olivier Laczka, CEO
“Over the past few months we have worked hard to prepare our data package to take to the FDA, and are anticipating a constructive engagement with their team.
“While we continue to actively investigate prospects for a near-term pilot study in a local Australian patient population, progressing down the US regulatory pathway is a key component of our overall strategy to boost SOF-SKN’s commercial attractiveness in the global marketplace.”
Understanding pre-IND meetings and the Sofra platform
Pre-IND meetings involve a discussion of the planned clinical development pathway along with topics such as product manufacturing, quality controls, and other requirements to support a comprehensive IND application.
SOF-SKN is built on the company’s Sofra technology platform. Sofra is based on the use of synthetic nucleic acids, known as oligonucleotides, to mimic natural regulators of the body’s defence system.
This approach is designed to enable selective and modular tuning of immune sensors, either reducing or stimulating their associated biological responses. The platform is focused on inflammatory and autoimmune diseases as well as immuno-oncology for cancer treatment.
Nature Immunology validation of the Sofra platform, published in February 2026 with endorsement from Professor Arthur Krieg, provided the independent, peer-reviewed scientific foundation that the FDA data package now builds upon, lending the oligonucleotide mechanism a level of credibility that supports both regulatory and partnering discussions.
The commercial opportunity behind SOF-SKN
SOF-SKN is initially being developed for the chronic inflammation caused by the autoimmune disease cutaneous lupus erythematosus (CLE). The company has flagged potential expansion into additional autoimmune-related skin diseases such as psoriasis and dermatomyositis.
The market context behind the programme is set out below.
| Market | Current Value | Projected Value | Relevance to NOX |
|---|---|---|---|
| Global CLE market | More than US$3.3 billion | Expected to grow significantly (not disclosed) | SOF-SKN initial target |
| Global autoimmune disease therapeutics | US$163.2 billion (2024) | US$219.6 billion (2035) | Sofra platform addressable market |
| Global immuno-oncology | US$43 billion (2023) | US$284 billion (2033) | Broader Sofra/Chroma opportunity |
Beyond dermatology, the underlying Sofra technology may also support future development opportunities across a broader range of diseases associated with immune system dysregulation, including rheumatoid arthritis and diabetes.
The next major ASX story will hit our subscribers first
What’s next for Noxopharm
The near-term roadmap disclosed by the company can be summarised as follows:
-
Pre-IND meeting with the FDA expected in around two months’ time
-
Continued investigation of a near-term pilot study in an Australian patient population
-
Preparation toward a future IND submission
Progress along the US regulatory pathway remains central to the company’s stated strategy of enhancing SOF-SKN’s global commercial value.
Noxopharm continues to build its pipeline across two technology platforms, Sofra (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma (oncology), spanning a range of indications from inflammation and autoimmunity through to cancer treatment.
Sofra immuno-oncology data published in May 2026 showed a more than 200-fold increase in immune activation biomarkers in human skin biopsies when the platform was combined with a clinical-stage agonist, illustrating how the same oligonucleotide technology underpinning SOF-SKN is being developed against a separate cancer opportunity projected to reach US$284 billion by 2033.
Don’t Miss the Next ASX Healthcare Breakthrough
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at Big News Blast to start receiving real-time alerts today.